Autonomix Medical has entered into a warrant inducement agreement with an existing investor expected to generate about $2.6 million in gross proceeds through the immediate exercise of warrants. Under the agreement, the investor will exercise November 2025 warrants to purchase 428,731 common shares at an amended exercise price of $6.00 per share. In exchange, Autonomix will issue two new unregistered warrant series, D-1 and D-2, each exercisable for 428,731 shares at an exercise price of $5.75 per share. The transaction is expected to close on or about July 15, with proceeds used for working capital and general corporate purposes.
Autonomix Medical, Inc. Common StockCompany raises $2.6M through warrant exercise, providing working capital.